NEW YORK – Genomic testing firm Veracyte has partnered with Acerta Pharma, the hematology research and development arm of AstraZeneca, to provide genomic information that will support Acerta's development of oncology therapeutics.
Financial and other terms were not disclosed.
"We are excited to partner with Acerta Pharma and AstraZeneca, global leaders whose innovative medicines are benefiting millions of patients worldwide," Veracyte Chairman and CEO Bonnie Anderson said in a statement. "This collaboration reflects the significant value we can bring to biopharmaceutical companies through our expanding global footprint, as well as our ability to potentially inform diagnosis and treatment decisions in new oncology indications."
In December, Veracyte acquired the exclusive diagnostics rights to globally license NanoString's nCounter platform and genomic tests in breast cancer and lymphoma